Dr-James-ChooJames J. Choo, MD is a native of Knoxville, TN.  He graduated from Emory University in 1999 with a Bachelor of Science in Anthropology, and received a Doctor of Medicine degree in 2004 from the University of Tennessee Health Science Center in Memphis.  After medical school, Dr. Choo completed his residency in anesthesia at the Ochsner Clinic Foundation in New Orleans, LA.  After residency, he attended the University of New Mexico and completed an ACGME-accredited pain fellowship.  Dr. Choo is ABMS board-certified in anesthesiology and pain medicine.

Dr. Choo serves as the Medical Director of PCET Surgery Center and as the primary investigator for PCET Research Center. He has also worked with state legislators, other medical providers, and law-enforcement providers with regard to pain-management legislation issues in Tennessee. He served on the Opioid Prescribing Committee for the Tennessee Medical Association in order to help craft legislation aimed at curbing presciption drug abuse while protecting chronic pain patients’ needs. This committee has developed opioid “best practices” guidelines for all physicians and mid-level providers in Tennessee who treat chronic pain.

Dr Choo has been voted a “Top Doc” for Pain Management by local area physicians in 2012, 2013, 2014, 2015, 2016, 2017, and 2018. The honor is published in Cityview Magazine.

Research Experience

  • Observation, Cross-Sectional, Multi-Center study involving Patient’s who will complete a set of Questionnaires for Neuropathic Pain. This study is non-Interventional and is eCRF and ePRO conducted. Served as Principal Investigator.
  • A Phase III, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of an oral investigational drug in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy. Served as Sub-Investigator.
  • A Multi-Center, Double-Blind, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of a Device for the Temporary Relief of Pain from Knee Osteoarthritis. Served as Principal Investigator.
  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients with Postherpetic Neuralgia. Principal Investigator
  • Characterization of Neuropathic Pain and its Subtype in the United States. To describe the characteristics of patients with a physician-confirmed diagnosis of NeP and of specific NeP subtypes. Principal Investigator.
  • A Phase 3, Randomized, Double Blind, Placebo and Active-Controlled, Multi-Center, Parallel-Group Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects with Chronic Low Back Pain. Principal Investigator.
  • A Phase 3 Randomized, Double Blind, Active Controlled, Multicenter Study of the Long Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects with Osteoarthritis of the Hip or Knee. Sub- Investigator.